2021 年第 4 期 第 16 卷

眩晕宁片治疗眩晕的临床效果观察

Clinical effect of Xuanyunning tablets on the treatment of vertigo

作者：柴滨1李萍2宋海涛3冯涛1

英文作者：Chai Bin1 Li Ping2 Song Haitao3 Feng Tao1

单位：1首都医科大学附属北京天坛医院神经病学中心运动障碍性疾病科100070；2首都医科大学附属北京天坛医院北京市神经外科研究所神经电生理室100070；3北京医院耳鼻喉科100730

英文单位：1Department of Neurodegenerative Disease Center of Neurology Beijing Tiantan Hospital Capital Medical University Beijing 100070 China; 2Neuroelectrophysiology Room Beijing Neurosurgical Institute Beijing Tiantan Hospital Capital Medical University Beijing 100070 China; 3Department of Otolaryngology Beijing Hospital Beijing 100730 China

关键词：眩晕；高刺激听性脑干反应；眩晕症状量表；眩晕宁片；甲磺酸倍他司汀片

英文关键词：Vertigo;Auditorybrainstemresponseofhigh-frequencystimulation;Vertigosyndromescale;Xuanyunningtablets;Betahistinemesilatetablets

• 摘要：

• 目的 观察眩晕宁片治疗相关疾病所致眩晕的临床效果。方法 选择2010年1—10月首都医科大学附属北京天坛医院和北京医院门诊就诊的良性阵发性位置性眩晕，单侧前庭病，单发眩晕为表现的后循环缺血眩晕患者300例。进行高刺激听性脑干反应检查异常者入组，采用随机、双盲、2∶2∶1阳性药物平行对照试验，分成眩晕宁组（120例）、联合组（120例）和倍他司汀组（60例）。进一步进行眩晕症状量表评分及静止姿势图检查，并对治疗前、后结果进行分析比较。结果 治疗前后51.1 Hz Ⅰ～Ⅴ间期与11.1 Hz Ⅰ～Ⅴ间期的差值均小于0.28，所以3组间差异无统计学意义（均P>0.05）。3组组内左侧治疗前后、右侧治疗前后2种频率Ⅰ～Ⅴ间期值之差差异均有统计学意义（均P<0.05）。倍他司汀组、联合组、眩晕宁组3组间治疗前、治疗后眩晕症状量表评分比较差异均无统计学意义（均P>0.05）。3组治疗后眩晕症状量表评分均低于治疗前，差异均有统计学意义（均P<0.001）。眩晕宁组及联合组治疗后睁眼及闭眼重心动摇总轨迹长度小于治疗前［眩晕宁组：（801±427）mm比（820±401）mm、（1 138±661）mm比（1 227±717）mm；联合组：（754±380）mm比（800±440）mm、（1 057±560）mm比（1 172±740）mm］，差异均有统计学意义（均P<0.05）；倍他司汀组治疗前后以上指标差异均无统计学意义（均P>0.05）。结论 眩晕宁片在改善眩晕症状方面临床效果显著，与甲磺酸倍他司汀片疗效相当，能有效改善良性阵发性位置性眩晕、单侧前庭病及以单发眩晕为表现的后循环缺血等疾患所致的眩晕症状，安全有效。

  
  

• Objective To observe the clinical effect of Xuanyunning tablets on the treatment of vertigo caused by related diseases. Methods From January to October 2010, 300 outpatient vertigo patients with posterior circulation ischemia(PCI) presenting with benign paroxysmal positional vertigo(BPPV), unilateral vestibular disease, single vertigo were selected from Beijing Tiantan Hospital, Capital Medical University and Beijing Hospital. Those who had irregular results on auditory brainstem response of high-frequency stimulation tests were selected to participate in the following clinical trial. A random, double-blinded, 2∶2∶1 positive drug parallel-controlled trial was conducted. The patients were divided into Xuanyunning group(120 cases), combined group(120 cases) and betahistine group(60 cases). Lastly, vertigo syndrome scale, and static balance instrument were applied, and the results were compared before and after treatment. Results The difference between 51.1 Hz Ⅰ-Ⅴ interval and 11.1 Hz Ⅰ-Ⅴ interval before and after treatment was less than 0.28, so there was no significant difference among the three groups(all P>0.05). There were statistically significant differences in the Ⅰ-Ⅴ interval differences of the left side and the right side before and after treatment within each group among the three groups(all P<0.05). There were no significant differences in the scores of vertigo symptom scale among betahistine group, combined group and Xuanyunning group before and after treatment(all P>0.05). The scores of vertigo symptom scale in three groups after treatment were lower than those before treatment, and the differences were statistically significant(all P<0.001). After treatment, the total track lengths of the center of gravity shaking after opening and closing eyes in the Xuanyunning group and the combined group were less than those before treatment［Xuanyunning group: (801±427)mm vs (820±401)mm, (1 138±661)mm vs (1 227±717)mm; combined group:(754±380)mm vs (800±440)mm, (1 057±560)mm vs (1 172±740)mm］(all P<0.05); there were no significant differences in the above indexes before and after treatment in betahistine group(all P>0.05). Conclusion Xuanyunning tablet has a significant clinical effect on ameliorating symptoms of vertigo, and  it is equivalent to betahistine mesilate tablets, which can effectively ameliorate symptoms of vertigo in patients with PCI presenting with BPPV, unilateral vestibular disease, single vertigo, with safety and efficacy.